Lode Wyns

Confo Therapeutics Appoints Paolo Vicini as Chief Development Officer

Retrieved on: 
Wednesday, June 3, 2020
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Clinical trials, Other Health, Flanders, Organizations, Biology, Science, Science and technology in Belgium, VIB, Vrije Universiteit Brussel, Vlaams Instituut voor Biotechnologie, Joost Schymkowitz, Lode Wyns

Confo Therapeutics today announced the appointment of Paolo Vicini, PhD, MBA, in the newly-created position of Chief Development Officer (CDO) effective June 1, 2020.

Key Points: 
  • Confo Therapeutics today announced the appointment of Paolo Vicini, PhD, MBA, in the newly-created position of Chief Development Officer (CDO) effective June 1, 2020.
  • With two decades of leadership and scientific experience in pharmaceutical research and development, Dr. Vicini joins Confo from his most recent position as Vice President, Development Sciences at Kymab.
  • Commenting on the appointment, Cedric Ververken, CEO of Confo Therapeutics said: Confo is focused on strategically expanding and shaping the Company to facilitate the rapid advancement of our first drug candidates.
  • Confo Therapeutics was spun out of Vrije Universiteit Brussel (VUB) and Vlaams Instituut voor Biotechnologie (VIB) in 2015.